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Abstract
Melanoma is the most aggressive and serious type of skin cancer. Known for being highly 
malignant and metastatic, melanoma typically has low survival rates. Prognosis can be 
improved with an early diagnosis and a good monitoring of the disease. However, cur-
rent melanoma biomarkers display severe limitations, making them inadequate for early 
detection of the malignancy. Therefore, it is of urgent matter for us to characterize and 
establish novel biomarkers with a direct application to daily clinics in order to accurately 
detect early american joint committee on cancer (AJCC) stages in melanoma patients, 
efficiently monitor the disease progression, and reliably predict the response to therapies, 
survival, and likely future recurrence. Long non-coding RNAs (lncRNAs) are a promis-
ing biomarker and regulator of tumor progression for many cancers. They are secreted 
into the bloodstream inside exosomes by a wide range of malignant cells and several of 
them have actually been validated as promising circulating molecular signatures of other 
cancer types, but not melanoma. However, in recent years there has been much research 
into lncRNA melanoma biomarkers, and many of them have been characterized as poten-
tially clinically relevant.
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1. Introduction
Melanoma is the most aggressive and serious type of skin cancer. Its propensity for rapid develop-
ment and ease of metastasis to vital organs such as the brain, lungs, and liver make it so deadly. 
Additionally, the incidence of melanoma in the United States has been consistently increasing since 
at least the 1970s [1]. Most importantly, early diagnosis predicts longer survival and better prognosis 
[2, 3]. This makes efficient and accurate diagnosis of melanoma a priority for clinicians. Thus, the 
continued exploration for accurate and efficacious biomarkers is a priority among cancer research.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
This chapter aims to describe various characterized and novel long non-coding RNAs (lncRNAs) 
as melanoma biomarkers. We will first explore the shortcomings and problems of current bio-
markers and how lncRNAs can serve as the potential future for melanoma markers. We will 
then look at already characterized lncRNAs such as BRAF-activated non-coding RNA (BANCR), 
Sprouty 4 (SPRY4), HOX transcript antisense RNA (HOTAIR), Metastasis-associated lung ade-
nocarcinoma transcript (MALAT), and Antisense non-coding RNA in the INK4 locus (ANRIL), 
as well as current research methods. Finally, we will discuss future perspectives and what we 
still need to do to adapt lncRNA for use as a melanoma biomarker.
2. The importance of early diagnosis
Melanoma is diagnosed as an AJCC stage I, II, III, or IV. Stages I and II are characterized as 
melanomas of varying Breslow thicknesses and possible ulceration, but with no lymph node 
involvement or metastases. Depending on the sub-stage, 5-year survival ranges from 53% to 
a robust 97% [4]. Stage III is characterized by regional metastases with 5-year survival rates 
of 40–78% depending on sub-stage [4]. Stage IV is characterized by distant metastases with 
extremely poor prognosis and 1-year survival rates ranging from 33 to 62% depending on 
location of metastases and serum LDH level [4].
There have been recent breakthroughs in melanoma treatments for stages IIIC and IV. Common 
therapies approved by the Food and Drug Administration include both immunotherapy and 
small molecule targeted therapy. Both immunotherapy drugs such as pembrolizumab (anti-PD-1) 
[5, 6], nivolumab (anti-PD-1) [7], and ipilimumab (anti-CTLA-4) [7, 8], and small molecules inhib-
itors such as dabrafenib (BRAF inhibitor) [9], vemurafenib (BRAF inhibitor) [10], and trametinib 
(MEK inhibitor) [11] have improved patient survival. However, most tumors become drug-resis-
tant shortly after commencing therapy, resulting in disease progression [12, 13]. Unfortunately, 
our current therapies are more of a temporary stay than a permanent cure.
Thus, the best way to ensure long-term survival is to diagnose the malignancy while it is in its 
early stages and slow disease progression through surgery and adjuvant therapy. Melanoma bio-
markers play an important role in the diagnosis and prediction of the progression of the disease. 
However, they have severe limitations in regard to precision to detect early stages of melanoma 
and reliability as a predictor of disease prognosis and treatment response. By understanding the 
molecular basis of the disease more, we can identify novel biomarkers that can be used to more 
efficiently diagnose disease which will undoubtedly improve outcomes and quality of life.
3. Current biomarkers in melanoma
According to the National Institutes of Health Biomarkers Definitions Working Group, bio-
markers, or “biological markers,” are “a characteristic that is objectively measured and 
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 evaluated as an indicator of normal biological processes, pathogenic processes, or pharma-
cologic responses to a therapeutic intervention” [14]. Biomarkers are commonly used in both 
clinical trials and clinical practice because of its multitude of applications: as diagnostics for 
identifying patient conditions or diseases, as a tool for staging and characterization of disease, 
as an indicator of disease progression, or as a predictor of treatment response [14].
Tumor markers are specifically biomarkers of cancer. They are usually proteins that are 
tumor-derived (produced by the tumor cells) or tumor-associated (produced by the body in 
response to tumor cells development) [15]. Tumor markers can appear in a variety of samples, 
but the most commonly used specimens for detection are blood serum and urine. Both are 
viable for these purposes because of the ease of collection and processing, as well as the secre-
tion of distinctive cancer markers into these fluids.
Proteins are the most common tumor marker because of their central roles in cell signaling 
and influence on key molecular pathways in various cells and systems of the body. They are 
often most easily measurable through immunohistochemistry as certain protein levels change 
between normal and tumor cells. However, many other molecules can also serve as tumor 
markers. Cell-free circulating tumor DNA (ctDNA) were characterized in the late 1980s and 
since then, it has been found that ctDNA is correlated with tumor size and disease activity [16, 
17]. ctDNA can be analyzed through liquid biopsies and PCR-based assays [18]. Circulating 
tumor cells (CTCs) are often present in advanced neoplasias that have metastatic potential and 
can be purified from serum on the basis of different cell surface markers compared to normal 
blood cells [18, 19]. Serum metabolites are small molecules secreted by tumor cells that can often 
serve as a signature of the tumor [20–22]. Carbohydrate expression also changes during onco-
genic transformation and cancer progression and can serve as a measure of cancer stage [23–25].
This chapter will specifically examine RNA as biomarkers. In recent years, differing tran-
scriptomes among tumor and healthy cells have become a point of emphasis. Several cancers 
have different noncoding RNA expression profiles in a time- and tissue-dependent manner. 
Changes in miRNA within a specific tissue has been shown to correlate with disease status 
including tumor invasiveness and metastatic potential in various cancers such as breast, 
colorectal, hepatic, lung, pancreatic, and prostate [26]. LncRNAs can also be used as serum 
tumor markers, which we will examine in detail in the following section.
4. lncRNAs as biomarkers for cancer
Much of our genome codes for RNA with no protein-coding potential. Such RNA is known 
as noncoding RNA. Long non-coding RNAs (lncRNAs) specifically refer to transcripts longer 
than 200 bp in length, and can reach up to over tens of kilobases in length. lncRNAs play a 
vital role in the regulation of many cellular processes especially gene-expression and post-
transcriptional activity. This is in part due to their structural versatility and ability to form 
ribonucleoprotein complexes (RNPs) [27].
LncRNAs as Biomarkers for Melanoma
http://dx.doi.org/10.5772/intechopen.70499
27
It has been noticed that lncRNA expression differs among normal and cancer cells, mak-
ing it a prime candidate for novel cancer research. Different studies have shown the 
diverse roles that lncRNAs play in cancer, helping malignant cells proliferate, resist 
apoptosis, evade growth suppression, maintain genomic instability, and invade and 
metastasize [28, 29].
What makes lncRNA so valuable as a potential biomarker is its accessibility and detection 
outside of the cell and in easily collectable biological samples such as blood and urine. 
LncRNAs are often found in high concentrations in exosomes [30], small cell-derived vesi-
cles 30–100 nm in diameter that are released from the plasma membrane to the extracellular 
environment. Thus, exosomes contain cytoplasm surrounded by a phospholipid bilayer, 
along with endosomal compartments known as multivesicular bodies (MVBs) that fuse 
with the plasma membrane before exosome release [31]. Exosomes contain many particles 
within the cytoplasm such as proteins and various nucleic acids like mRNA, lncRNA, and 
miRNA [31]. They are also able to communicate with both the immediate extracellular envi-
ronment and distant sites for potential metastases in the case of cancer cell exosomes [32]. 
Additionally, studies have demonstrated that compared to normal cells, cancer cells secrete 
more and differently constituted exosomes [31, 33, 34].
Exosomes can transfer molecules from cell to cell, and often, they end up in blood or waste to 
be excreted. It is simple to isolate these vesicles from blood serum or urine, and then analyze 
its components. Thus, we can use these molecules, including lncRNAs, as a tumor fingerprint 
to identify potentially tumorigenic cells. The use of exosome particles to identify cancers has 
already been demonstrated in gastric [35] and pancreatic cancer [36], among others. These circu-
lating lncRNA have already been shown to have great potential as biomarkers for several can-
cers, which make it all the more promising that some lncRNA can be effective in diagnosing and 
monitoring melanoma. For example, the expression of the gene DD3PCA3 is highly upregulated 
in prostate cancer cells compared to normal cells [37]. Traditionally, prostate specific antigen 
(PSA) is a protein biomarker used to test for prostate cancer. However, because the DD3PCA3 test 
has better specificity, it is now used in conjunction with PSA testing (along with TMPRSS2:ERG 
fusion RNA) to form a more specific test for this cancer. Other examples include MALAT1 in 
lung cancer, H19 and LINC00152 in gastric cancer, and HOTAIR in colorectal cancer and oral 
squamous cell cancer [38].
5. Potential lncRNAs as biomarkers for melanoma
Currently, lncRNAs are being used as biomarkers in many different malignancies, as outlined 
in the previous section. However, there is currently no reported usage of lncRNAs as mela-
noma biomarkers in a clinical setting. Various lncRNAs are still being tested as potentially 
viable clinical melanoma biomarkers, including many lncRNA upregulated in and/or used as 
a tumor marker for other cancers. A brief overview of each is provided here and a summary 
in Table 1. Known mechanisms of action are presented in Figure 1A–I.
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5.1. Antisense non-coding RNA in the INK4 locus (ANRIL)
Antisense non-coding RNA in the INK4 locus (ANRIL) is a 3834 nt lncRNA consisting of 19 
exons alternatively spliced in the antisense direction of the p15/CDKN2B-p16/CDKN2A-p14/
ARF gene cluster on chromosome 9 in humans. ANRIL interacts with polychrome repressive 
complexes 1 and 2 (PRC1/2) to reduce the expression of essential tumor suppressor proteins 
p15INK4b and p16INK4a. It has been shown that ANRIL can promote epithelial to mesen-
chymal transition (EMT) and metastasis in cancers such as non-small cell lung carcinoma and 
pancreatic [39, 40]. Although a research group used genome wide association studies (GWAS) 
to determine several single nucleotide polymorphisms in the ADP ribosylation factor (ARF) 
locus, including one within the ANRIL sequence, rs1011970, is associated with melanoma, we 
know little else about ANRIL’s potential role in melanoma. As such, further investigation is 
needed to determine its suitability as a melanoma biomarker.
5.2. BRAF-activated non-coding RNA (BANCR)
BRAF-activated non-coding RNA (BANCR) is a 693 bp lncRNA transcript highly induced by 
oncogenic BRAF and overexpressed in melanoma. More than 70% of melanomas contain an 
Melanoma lncRNA Full name Function
ANRIL Antisense non-coding RNA in INK4 locus Promotes EMT and metastasis
BANCR BRAF-activated non-coding RNA Implicated in cell survival, proliferation, 
and metastasis, expression correlated with 
disease progression
CASC15 Cancer susceptibility candidate 15 Increases migration and metastatic activity, 
prognosticator of melanoma stage
HOTAIR HOX transcript antisense RNA Promotes EMT and metastasis, prognostic 
role and serum marker in other cancers
Llme23 – Inhibits tumor suppressor; plays oncogenic 
role
MALAT-1 Metastasis-associated lung adenocarcinoma 
transcript 1
Migration and metastasis, overexpression 
activates MAPK, Wnt/beta-catenin
SAMMSON Survival associated mitochondrial 
melanoma-specific oncogenic non-coding 
RNA
Promotes cancer cell survival
SLNCR1 – Promotes EMT and invasion
SNHG5 SnoRNA host gene 5 Melanoma invasion and metastasis
SPRY4-IT1 – Promotes melanoma cell growth and 
invasion and blocks apoptosis
UCA-1 Urothelial carcinoma-associated 1 Promotes invasion and metastasis
Table 1. Summary of melanoma lncRNA.
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activating BRAF mutation, of which 90% is the V600E mutant. Mutant BRAF causes the upreg-
ulation of various proteins and transcripts implicated in cell survival, proliferation, and metas-
tasis, including BANCR. BANCR is overexpressed in both melanoma cell lines and tissues, 
with increased expression correlated with disease progression [41, 42]. Flockhart et al. first 
characterized BANCR as regulating melanoma cell migration [41]. Perhaps unsurprisingly, 
patients with high levels of BANCR had a much lower survival rate than patients with low 
levels of BANCR (3-year survival of 40% compared to 71%) [42]. So far, research on BANCR 
has shown its potential value as both a target for therapy as well as a prognostic measure. 
Figure 1. This figure displays the pathways and mechanisms of action of potential melanoma lncRNAs. Growth and 
proliferation: ANRIL, BANCR, Llme23, MALAT-1, UCA1 (A–E). Invasion and metastases: HOTAIR, SLNCR1 (F–G). 
Apoptosis: SAMMSON, SPRY4-IT1 (H–I). Mechanism not yet characterized: SNGH5, CASC15.
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However, there have been few studies to validate its efficacy. Additionally, its presence in 
serum, which would make it a more viable biomarker, has not yet been demonstrated.
5.3. Cancer susceptibility candidate 15 (CASC15)
Cancer susceptibility candidate 15 (CASC15) is a 530 kb intergenic lncRNA (lincRNA) on 
chromosome six that was observed to be actively transcribed in metastatic melanoma. 
Its expression increases migration and metastatic activity, although its mechanism of 
action and binding partners is currently unknown [43]. A study found that CASC15 was 
both expressed in melanoma cell lines and upregulated in a mouse xenograft model of 
brain metastases [44]. Additionally, CASC15 can serve as a good prognosticator of mela-
noma stage, as levels increase during melanoma progression, with significant expression 
in advanced stage IV metastases compared to controls and melanoma in situ (MIS) [44]. 
However, while normal tissue shows virtually undetectable levels of CASC15, other cancers 
can also show high levels of CASC15 expression, making it less specific than other biomark-
ers [44]. Nonetheless, if it is indeed possible to isolate CASC15 in blood or urine samples of 
melanoma patients, which to date has not been done, it can serve as a valuable diagnostic 
and prognosticator of metastatic melanoma.
5.4. HOX transcript antisense RNA (HOTAIR)
HOX transcript antisense RNA (HOTAIR) is a 2.2 kilobase lncRNA in an intronic region of 
the HOXC gene locus. HOTAIR is believed to regulate gene expression through chromatin 
remodeling; it promotes epithelial-mesenchymal transition (EMT) and cancer metastasis by 
coordinating with polycomb repressive complex 2 (PRC2) to repress the expression of vari-
ous genes suppressing metastasis [45, 46]. Its net effect in metastatic melanoma is to promote 
motility, invasion, and metastatic potential [47], evidenced by its upregulation in metastatic 
tissue. HOTAIR’s role as a prognostic factor in breast cancer is well characterized, and it may 
also serve prognostic roles in gastroenteric tumors and liver metastases [45]. Additionally, its 
potential as a serum biomarker in other cancers has been documented [48, 49]. It may serve a 
similar capacity in melanoma, but more research still needs to be done, including verification 
of its presence in serum.
5.5. Llme23
Llme23 is a 1600 bp lncRNA expressed exclusively in melanoma. It was first discovered through 
identifying lncRNA binding partners to polypyrimidine tract-binding (PTB) protein-associated 
splicing factor (PSF) via RNA-SELAX affinity chromatography [50]. PSF is a tumor suppressor 
repressing the transcriptional activity of multiple proto-oncogenes, including Rab23 [50]. Llme23 
interacts with and subsequently blocks the function of PSF, thus inhibiting its tumor suppressor 
function [50]. Because of its exclusive nature to melanoma cell lines, Llme23 would serve as a 
highly specific biomarker for melanoma. Before it can be adapted to clinical use, further research 
is required to determine its secretion and levels in plasma and/or urine.
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5.6. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1)
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), also known as nuclear-
enriched transcript 2 (NEAT2) is a well-characterized, roughly 8000 bp lncRNA. It has been 
extensively studied and shown to have a regulatory function lung cancer cell migration and 
metastasis [51], as well as similar roles in liver cancer [52], thyroid cancer [53], and neuro-
blastoma [54]. MALAT-1 targets many tumor suppressor genes, and its overexpression acti-
vates MAPK, Wnt/beta-catenin, p53, caspase-3, caspase-8, and the Bax signaling pathway. Its 
relevance to melanoma has recently come to attention, as Tian et al. found that MALAT-1 is 
highly expressed in melanoma tumors compared to normal tissues [55]. Moreover, metastatic 
sites display higher levels of MALAT-1 than primary tumors [55]. MALAT-1 is a promising 
new biomarker for melanoma, as its presence in serum and urine has already been reported in 
prostate cancer patients [56, 57].
5.7. Survival associated mitochondrial melanoma-specific oncogenic non-coding RNA 
(SAMMSON)
Survival associated mitochondrial melanoma-specific oncogenic non-coding RNA (SAMMSON) 
is located around 30 kb downstream of microphthalmia-associated transcription factor (MITF), 
an oncogene specific to melanoma. Although SAMMSON and MITF are only co-amplified in 
around 10% of melanomas, SAMMSON itself was detected in 90% of melanoma samples from 
the TCGA RNA-seq data set [58]. SAMMSON binds to p32, which regulates tumor metabo-
lism through balancing oxidative phosphorylation and glycolysis [58, 59]. Knockdown of 
SAMMSON resulted in decreased cell viability and apoptosis. SAMMSON localizes to the 
mitochondria, so its presence in serum may be limited. However, further investigations should 
be done to confirm its potential as a biomarker.
5.8. SLNCR1
SLNCR1 is a lncRNA that promotes melanoma invasion and is associated with survival outcome. 
The brain-specific homeobox protein 3a (Brn3a) and androgen receptor (AR) binds to SLNCR1 to 
increase melanoma invasion by activating the transcription of MMP9, required for the degrada-
tion of extracellular matrix during EMT and invasion [60]. Interestingly, the higher incidence of 
melanoma metastases in males compared to females may be explained by ARs being binding 
partners for SLNCR1 [60]. Again, there is presently no research on the presence of SLNCR1 in 
plasma and thus its viability as a melanoma biomarker.
5.9. SnoRNA host gene 5 (SNHG5)
SnoRNA host gene 5 (SNHG5) is a 524 bp lncRNA whose levels were found to be signifi-
cantly higher in the serum of patients with melanoma compared to normal subjects as well 
as patients with squamous cell carcinoma [61]. This suggests that this lncRNA plays a role in 
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melanoma formation and/or metastasis. Its presence in serum is already documented, making 
it a promising biomarker. However, much more research needs to be done as its mechanism 
in melanoma has yet to be characterized and the only study looked at just 24 patients with 
malignant melanoma [61].
5.10. SPRY4-IT1
SPRY4-IT1 is a lncRNA located within the intron of the Sprouty 4 (SPRY4) gene. It was first 
identified as upregulated in melanoma cells compared to melanocyte and keratinocyte con-
trols [62]. SPRY4-IT1 promotes melanoma cell growth and invasion and also blocks apoptosis 
[62]. It acts by binding to and inactivating lipin 2, an enzyme involved in fatty acid metabo-
lism [63]. Knockdown of SPRY4-IT1 induces an increase of lipids in the cell and can lead to 
apoptosis due to lipotoxicity [63]. Based on plasma samples of healthy individuals (N = 79) 
and malignant melanoma patients (N = 70), SPRY4-IT1 expression was significantly higher in 
malignant melanoma patients. Additionally, elevated SPRY4-IT1 significantly reduced patient 
survival rate and is strongly associated with more advanced tumor stage [64]. These data 
suggest that SPRY4-IT1 may be used as a marker for both diagnosis and staging. SPRY4-IT1 
was also found to be present in the plasma of esophageal squamous cell carcinoma patients, 
and associated with poor prognosis [65]. Limitations of its efficacy as a melanoma biomarker 
include specificity, as it is also found to play roles in prostate cancer [66], glioma [67], and 
gastric cancer [68], among others.
5.11. Urothelial carcinoma-associated 1 (UCA-1)
Urothelial carcinoma-associated 1 (UCA-1) is a 1.4 kb lncRNA implicated in several cancers 
including breast, gastric, and pancreatic [69–71]. A recent study by Wei et. al. showed that 
UCA-1 is upregulated in melanoma as well [72]. It acts by inactivating miR-507, which in turn 
leads to the upregulation of transcription factor FOXM1 mRNA and invasion and metastasis 
[72]. Studies have shown that urine UCA-1 is a possible diagnostic biomarker in bladder cancer 
[73], though it has not yet been tested as a marker for melanoma.
6. Research and clinical methods
One common method of identifying novel lncRNAs is by RNA-seq expression profiles between 
cancer cells and normal cells expressing relevant oncogenes [41]. BANCR was discovered 
through this method. Previously, Sanger sequencing of cDNA libraries and tiling arrays were 
the preferred method for identifying lncRNA, but they have since been replaced by RNA-seq 
and other next generation sequencing technologies [74].
To characterize the mechanism of lncRNA action, it is important to determine subcellular 
localization and binding partners. To determine the subcellular localization of a particu-
lar, fluorescence in situ hybridization (FISH) may be used. To find molecular interactions 
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between the lncRNA and DNA, RNA, and proteins, a variety of pull-down experiments are 
performed (Figure 2A). To determine RNA-DNA interactions, chromatin isolation by RNA 
purification (ChiRP) is most commonly used. Other methods include RNA antisense puri-
fication (RAP), which uses RNA antisense probes to map RNA interactions with chromatin 
Figure 2. Experimental techniques. (A) General workflow for immunoprecipitations. Many of these pull-down 
experiments to find RNA binding partners follow a similar protocol, including ChIRP, RAP RNA, and RIP. RNA-DNA: 
ChIRP, RAP, CHART. RNA-RNA: RAP RNA, CLASH. RNA-protein: RIP, CLIP. (B) Clinical detection of circulating 
lncRNA. lncRNA are found in serum exosomes. First, a blood sample collected from a patient is centrifuged to separate 
the plasma. Then, exosomes are precipitated from the plasma, lysed, and RNA collected and purified. This purified RNA 
can then be analyzed via RT-qPCR to identify any lncRNAs of interest.
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[75], and capture hybridization analysis of RNA targets (CHART), which uses capture oli-
gonucleotides that hybridize to the RNA of interest, which is then enriched alongside its 
targets [76]. To determine RNA-RNA interactions, RAP RNA or cross-linking, ligation, and 
sequencing of hybrids (CLASH), may be used. RAP RNA uses differential cross-linking with 
psoralen for RNA-RNA interactions and formaldehyde for protein-mediated RNA-RNA 
interactions [77]. CLASH, a less labor-intensive method, uses UV cross-linking and sequenc-
ing of ligated RNA-RNA hybrids, whereupon chimeric reads are identified using bioinfor-
matics [78]. To determine RNA-protein interactions, RNA immunoprecipitation (RIP) can 
be used to analyze RNA associations with proteins at specific time points [79], while cross-
linking immunoprecipitation (CLIP) maps RNA-protein interactions through in vivo UV 
cross-linking of cells [80].
Clinically, the detection of circulation lncRNA for use in diagnostics and monitoring would be 
simple (Figure 2B). First, plasma exosomes would need be isolated from a patient’s blood sample. 
Centrifugation of the blood sample first separates the plasma from the cellular components, and 
the exosomes can then be precipitated from the plasma using one of several techniques: ultra-
centrifugation, size-exclusion chromatography/ultrafiltration, immunoaffinity capture-based 
technique, or use of a commercial, exosome precipitation kit [81]. Ultracentrifugation involves 
spinning the sample at forces up to 1,000,000 g, and is considered the most effective and most 
used method [81]. Second, RNA extraction for lncRNA analysis would need to be done. The exo-
somes are lysed, RNA extracted and purified, and then analyzed using qRT-PCR.
7. Conclusion: the future of lncRNAs in melanoma as biomarkers and 
targets for therapy
Overall, lncRNAs serve as promising biomarkers for melanoma, though much more research 
needs to be done on them before they can be used clinically. The presence of lncRNA in blood 
and urine make them particularly valuable to the field of cancer diagnostics as presently, there 
is a dearth of early diagnostic measures for melanoma. Currently, potential melanomas must 
be detected by a patient or physician. The major shortcoming of this is that sometimes malig-
nant melanomas do not appear obvious until it is at a late stage, and patients themselves often 
cannot identify harmful lesions at early stages. Additionally, it is difficult to keep track of 
potentially malignant nevus in certain areas of the body. Once a potentially tumorigenic nevus 
or lesion is clinically observed, the first line of diagnostics is the histopathology of biopsies, 
which are both invasive and expensive.
Diagnoses using circulating lncRNA could serve as an improvement to these biopsies. Not only 
are they minimally invasive, they are also less expensive and can be conducted at regular inter-
vals for high-risk patients (those with a melanoma in the past 5 years, certain genes, phenotypic 
red hair, Irish-Scottish ancestry, high mole count, frequent sun exposure, etc.). Moreover, many 
lncRNAs can also provide valuable prognostic information, including progression, staging, 
and size to tumor.
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Some concerns for the use of lncRNA as biomarkers do exist. The lncRNA must be present 
in sufficient quantity for it to be able to be detected and analyzed using standard methods. 
Additionally, as discussed previously, many of these lncRNAs are also upregulated in other 
cancers, lowering its specificity as a melanoma biomarker. However, this may not be a bad 
thing, as other malignancies may be able to be “accidentally” detected.
Certain lncRNA can also be used as targets for novel therapies. LncRNAs like BANCR and 
MALAT-1 are responsible for cell migration and metastases. Targeting or knocking down 
these lncRNA in vivo may prevent further progression and invasion of early stage melanomas 
and limit the metastatic activity of late stage melanomas.
In conclusion, lncRNAs are likely to be suitable melanoma biomarkers for a variety of rea-
sons: (1) They are secreted into the bloodstream and easily accessible for analysis using non-
invasive and inexpensive methods. Because they are secreted within exosomes, they are also 
protected from various RNases within the bloodstream. (2) Various lncRNAs are secreted at 
different time-points of disease progression. Those secreted early on have valuable diagnos-
tic potential while others may be useful in determining disease development and prognosis. 
(3) LncRNAs are generally highly specific for melanoma, a shortcoming of current protein 
biomarkers. (4) Noncoding RNAs are responsible for a variety of cellular functions and impli-
cated in many important pathways, making them valuable prognosticators of disease. (5) 
LncRNA biology is still a relatively novel field, which holds a lot potential as more research 
is being conducted.
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